Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
View/ Open
Date
2017-09-01ICR Author
Author
Smyth, EC
Wotherspoon, A
Peckitt, C
Gonzalez, D
Hulkki-Wilson, S
Eltahir, Z
Fassan, M
Rugge, M
Valeri, N
Okines, A
Hewish, M
Allum, W
Stenning, S
Nankivell, M
Langley, R
Cunningham, D
Type
Journal Article
Metadata
Show full item recordAbstract
IMPORTANCE: Mismatch repair (MMR) deficiency (MMRD) and microsatellite instability (MSI) are prognostic for survival in many cancers and for resistance to fluoropyrimidines in early colon cancer. However, the effect of MMRD and MSI in curatively resected gastric cancer treated with perioperative chemotherapy is unknown. OBJECTIVE: To examine the association among MMRD, MSI, and survival in patients with resectable gastroesophageal cancer randomized to surgery alone or perioperative epirubicin, cisplatin, and fluorouracil chemotherapy in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. DESIGN, SETTING, AND PARTICIPANTS: This secondary post hoc analysis of the MAGIC trial included participants who were treated with surgery alone or perioperative chemotherapy plus surgery for operable gastroesophageal cancer from July 1, 1994, through April 30, 2002. Tumor sections were assessed for expression of the MMR proteins mutL homologue 1, mutS homologue 2, mutS homologue 6, and PMS1 homologue 2. The association among MSI, MMRD, and survival was assessed. MAIN OUTCOMES AND MEASURES: Interaction between MMRD and MSI status and overall survival (OS). RESULTS: Of the 503 study participants, MSI results were available for 303 patients (283 with microsatellite stability or low MSI [median age, 62 years; 219 males (77.4%)] and 20 with high MSI [median age, 66 years; 14 males (70.0%)]). A total of 254 patients had MSI and MMR results available. Patients treated with surgery alone who had high MSI or MMRD had a median OS that was not reached (95% CI, 11.5 months to not reached) compared with a median OS among those who had neither high MSI nor MMRD of 20.5 months (95% CI, 16.7-27.8 months; hazard ratio, 0.42; 95% CI, 0.15-1.15; P = .09). In contrast, patients treated with chemotherapy plus surgery who had either high MSI or MMRD had a median OS of 9.6 months (95% CI, 0.1-22.5 months) compared with a median OS among those who were neither high MSI nor MMRD of 19.5 months (95% CI, 15.4-35.2 months; hazard ratio, 2.18; 95% CI, 1.08-4.42; P = .03). CONCLUSIONS AND RELEVANCE: In the MAGIC trial, MMRD and high MSI were associated with a positive prognostic effect in patients treated with surgery alone and a differentially negative prognostic effect in patients treated with chemotherapy. If independently validated, MSI or MMRD determined by preoperative biopsies could be used to select patients for perioperative chemotherapy.
Collections
Subject
Humans
Stomach Neoplasms
Cisplatin
Fluorouracil
Epirubicin
DNA-Binding Proteins
Antineoplastic Combined Chemotherapy Protocols
Prognosis
Chemotherapy, Adjuvant
Gastrectomy
Survival Rate
Adult
Aged
Middle Aged
Female
Male
MutS Homolog 2 Protein
Microsatellite Instability
DNA Mismatch Repair
MutL Protein Homolog 1
Mismatch Repair Endonuclease PMS2
Research team
Medicine (RMH Smith Cunningham)
Gastrointestinal Cancer Biology and Genomics
Language
eng
Date accepted
2016-11-30
License start date
2017-09
Citation
JAMA oncology, 2017, 3 (9), pp. 1197 - 1203
Publisher
AMER MEDICAL ASSOC